Counterpoint: The Argument for Combination Chemotherapy in the Treatment of Metastatic Breast Cancer

View More View Less
  • 1 From Northwestern University, Feinberg School of Medicine, Chicago, Illinois.

The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: William J. Gradishar, MD, Northwestern University, Feinberg School of Medicine, 676 North St. Clair, Suite 850, Chicago, IL 60611. E-mail: w-gradishar@northwestern.edu
  • 1.

    Fossati R, Confalonieri C, Torri V. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:34393460.

    • Search Google Scholar
    • Export Citation
  • 2.

    Carrick S, Parker S, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;CD003372.

    • Search Google Scholar
    • Export Citation
  • 3.

    O'Shaughnessy J, Miles D, Vukelja S. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:28122823.

    • Search Google Scholar
    • Export Citation
  • 4.

    O'Shaughnessy J, Nag S, Calderillo-Ruiz G. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pretreated metastatic breast cancer (MBC): interim results of a global phase III study [abstract]. Proc Am Soc Clin Oncol 2003;22(Suppl 1):Abstract 25.

    • Search Google Scholar
    • Export Citation
  • 5.

    Albain KS, Nag S, Calderillo-Ruiz G. Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as front-line therapy for metastatic breast cancer (MBC): first report of overall survival [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 6.

    Miles D, Vukelja S, Moiseyenko V. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004;5:273278.

    • Search Google Scholar
    • Export Citation
  • 7.

    Sledge GW, Neuberg D, Bernardo P. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588592.

    • Search Google Scholar
    • Export Citation
  • 8.

    Smalley RV, Murphy S, Huguley CM, Bartolucci AA. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 1976;36:39113916.

    • Search Google Scholar
    • Export Citation
  • 9.

    Yamamoto N, Watanabe T, Katsumata N. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:24012408.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 45 26 0
PDF Downloads 20 9 1
EPUB Downloads 0 0 0